ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Nucleic Acid Point-of-Care Testing to Improve Diagnostic Preparedness.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Portable Molecularly Imprinted Polymer Sensor for Rapid Swab-Based Detection of Norovirus.Advanced healthcare materials · 2026Article
- SAFE: a Mix-and-Read Assay for miRNA Detection in Extracellular Vesicles From Unprocessed Plasma Toward Clinical Disease Diagnosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Review
- The future of diagnostics in Africa.Nature medicine · 2026Review
- Enhanced SfaTnpB enables single-base-specific, one-pot nucleic acid detection for high-sensitivity diagnostics.Nucleic acids research · 2026Article
- Enhancing Global Health Security in Sub-Saharan Africa: The case for integrated One Health surveillance against zoonotic diseases and environmental threats.One health (Amsterdam, Netherlands) · 2025Review
- How to identify respiratory pathogens in primary health care - a review on the benefits, prospects and pitfalls in using point of care tests.Infection · 2025Review
- Rapid and sensitive detection of OXA-23-mediated carbapenem resistance in Acinetobacter baumannii using a paper-based immunoassay with silver-based signal amplification.Mikrochimica acta · 2025Article
- A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings.Life science alliance · 2025Article
- Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in Germany.Advances in therapy · 2025Article
- Machine learning in point-of-care testing: innovations, challenges, and opportunities.Nature communications · 2025Review
- Implementation of Point-of-Care PCR-testing for the diagnosis of respiratory infections in vulnerable patient populations.PloS one · 2025Article
- Commercial Opportunity or Addressing Unmet Needs-Loop-Mediated Isothermal Amplification (LAMP) as the Future of Rapid Diagnostic Testing?Diagnostics (Basel, Switzerland) · 2024Article
- Implementing L-DNA analogs as mirrors of PCR reactant hybridization state: theoretical and practical guidelines for PCR cycle control.Analytical methods : advancing methods and applications · 2024Article
- Bioluminescent Intercalating Dyes for Ratiometric Nucleic Acid Detection.ACS chemical biology · 2024Article
- Optimization of a rapid and sensitive nucleic acid lateral flow biosensor for hepatitis B virus detection.Molecular biology reports · 2023Article
- Direct Nasal Swab for Rapid Test and Saliva as an Alternative Biological Sample for RT-PCR in COVID-19 Diagnosis.Microbiology spectrum · 2022Article
- Saliva-based methods for SARS-CoV-2 testing in low- and middle-income countries.Bulletin of the World Health Organization · 2022Article
- Clinical Performance of Self-Collected Nasal Swabs and Antigen Rapid Tests for SARS-CoV-2 Detection in Resource-Poor Settings.Biomedicines · 2022Article
- A Review of the Nucleic Acid-Based Lateral Flow Assay for Detection of Breast Cancer from Circulating Biomarkers at a Point-of-Care in Low Income Countries.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testing programs for severe acute respiratory syndrome coronavirus 2 have relied on high-throughput polymerase chain reaction laboratory tests and rapid antigen assays to meet diagnostic needs. Both technologies are essential; however, issues of cost, accessibility, manufacturing delays, and performance have limited their use in low-resource settings and contributed to the global inequity in coronavirus disease 2019 testing. Emerging low-cost, multidisease point-of-care nucleic acid tests may address these limitations and strengthen pandemic preparedness, especially within primary healthcare where most cases of disease first present. Widespread deployment of these novel technologies will also help close long-standing test access gaps for other diseases, including tuberculosis, human immunodeficiency virus, cervical cancer, viral hepatitis, and sexually transmitted infections. We propose a more optimized testing framework based on greater use of point-of-care nucleic acid tests together with rapid immunologic assays and high-throughput laboratory molecular tests to improve the diagnosis of priority endemic and epidemic diseases, as well as strengthen the overall delivery of primary healthcare services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.